Taken together, our results highlight the rationale of combining approaches targeting TAMs [60] and immune checkpoint molecules to increase tumor surveillance by CD8+ T cells, and make HNSCC more responsive to anti-PD-1 treatment, particularly in HPV-negative patients. The gene discussed is CD8A; the disease is head and neck squamous cell carcinoma.